Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amelogenin (None established; sometimes referred to as AMELX (for X-linked form) or AMELY (for Y-linked form))
- Target
- None established; sometimes referred to as AMELX (for X-linked form) or AMELY (for Y-linked form)
- Molecular classification
- Extracellular matrix protein, Structural protein, Cell adhesion protein, Other (not an enzyme, transporter, receptor, ion channel, etc.)
01
Overview
Amelogenin is the principal extracellular matrix protein in developing tooth enamel, constituting about 90% of enamel matrix proteins. It is coded by two genes: AMELX (X chromosome) and AMELY (Y chromosome), with the X gene producing the majority of the protein. Amelogenin exhibits several isoforms due to alternative splicing and proteolytic processing. Its biological function is to regulate the initiation, growth, and organization of hydroxyapatite crystals, leading to the formation of hard, organized tooth enamel. The structure of amelogenin enables it to self-assemble into nanospheres that guide enamel mineralization. Mutations in the AMELX gene cause amelogenesis imperfecta, a genetic disorder characterized by defective enamel. The gene is used in forensic science for sex determination due to its distinct chromosomal locations. As a structural matrix protein, amelogenin is not a classic therapeutic target for drugs, but its genetic mutations serve as biomarkers for certain dental disorders.
- Other names
- Amelogenesis imperfecta 1, X-linkedAmelogenin, X-linkedAMELX_HUMANAMGAMGLAMGXAIH1
02
Mechanism of action
Not applicable; amelogenin is not a therapeutic drug target and no drugs act directly on it
03
Biological functions
Tooth enamel developmentEnamel matrix organizationBiomineralization (regulation of hydroxyapatite crystallite formation and growth)Cell adhesion
04
Disease associations
Amelogenesis imperfecta (disease caused by mutations in the amelogenin gene resulting in abnormal tooth enamel development)Other roles currently not well-established
05
Safety considerations
None associated with therapeutic targeting, as amelogenin is not currently a drug targetTherapeutic challenges are limited to gene mutation effects, namely the risk and severity of enamel defects in amelogenesis imperfecta
06
Interacting drugs
None known; there are currently no drugs that directly target amelogenin
07
Biomarkers
Genetic markers for sex determination (due to different gene locations on X and Y chromosomes, used in forensic science)Mutations as a diagnostic marker for amelogenesis imperfecta
Beyond the preview
Go deeper on Amelogenin (None established; sometimes referred to as AMELX (for X-linked form) or AMELY (for Y-linked form)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amelogenin (None established; sometimes referred to as AMELX (for X-linked form) or AMELY (for Y-linked form)).